NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES Amendment No. 50

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee				In accordance with letter dated		4.	4. Expiration Date: November 30, 2023		
1.	Porter Regional Hospital			September 22, 2017.					
2.	85 East U.S. Highway 6 Valparaiso, IN 46383	-	230			er: 13-17073-01 is s entirety to read a			et No.: 030-12150 rence No.:
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical fo	nim. Z	/ \n	Maximum amount that nay possess at any on under this license		9.	Authorized use
A.	Any byproduct material permitted by 10 CFR 35.100	Α.	Any O		A. A	Is Needed	SIM	Α.	For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
. В.	Any byproduct material permitted by 10 CFR 35.200	В.	Any H	and a	B	As Needed		Β.	For use in imaging and localization studies permitted by 10 CFR 35.200.
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any	学校	C. 2	2 curies total		С.	For any use permitted by 10 CFR 35.300.
D.	Iridium-192 permitted by 10 CFR 35.400	D.	Sealed Sources (Best M International, Inc., Mode		D. 2	2 curies total		D.	For any manual brachytherapy procedure permitted by 10 CFR 35.400.
E.	lodine-125 permitted by 10 CFR 35.400	E.	Sealed Sources (Bard Brachytherapy, Inc, Mod 1251)		E. 2	2 curies total		E.	For any manual brachytherapy procedure permitted by 10 CFR 35.400.

κυ	FORM 374A	U.S. NUCLEAR REGULAT	ORY COMMISSION	PAGE 2 OF 4 PAGES			
	MATERIALS LICENSE	License Number 13-17073-01	Docket or Reference Number 030-12150	Pr			
	SUPPLEMENTARY SHEET	Amendment No. 50					
ð.	Byproduct, source, 7. Chemical and and/or special nuclear material	m	aximum amount that licensee 9. Au ay possess at any one time der this license	thorized use			
=.	10 CFR 35.1000 Technology		CI Lii	r medical use as permitted by 10 FR 35.1000 in a Sirtex Medical nited brachytherapy afterloader livery system.			
	CONDITIONS 0. A. Licensed material may be used or stored at the licensee's facilities located at 85 East U.S. Highway 6, Valparaiso, Indiana.						
	B. Licensed material in Subitem Nos. 6. Chesterton, Indiana and at Porter Ph	A. and 6.B. may be used or sto	ored at the licensee's facilities loca	ated at 1505 South Calumet,			
1	. The Radiation Safety Officer (RSO) for th	is license is James M. Forde,	MD.				
12	. Licensed material shall only be used by,	or under the supervision of:	NO NO				
	 A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: 						
,							
	Authorized User(M.D.,D.O.,etc.)	Material and Use					
		Material and Use 10 CFR 35.400					
	Authorized User(M.D.,D.O.,etc.)	10 CFR 35.400	d 35.300 (limited to the oral admir	nistration of sodium iodide I-131)			
	<u>Authorized User(M.D.,D.O.,etc.)</u> Koppolu P. Sarma, M.D.	10 CFR 35.400	d 35.300 (limited to the oral admir	nistration of sodium iodide I-131)			

FORM 374A	U.S. NUCLEAR REGULATORY C	PAGE 3 OF 4 PAGES	
MATERIALS LICENSE	License Number 13-17073-01	Docket or Reference Number 030-12150	
SUPPLEMENTARY SHEET	Amendment No. 50		
Authorized User(M.D.,D.O.,etc.)	Material and Use		
John A. Forchetti, M.D. Hector J. Marchand, M.D.	10 CFR 35.100 and 35.200 10 CFR 35.200 REG/		
Vivek Mishra, M.D.	10 CFR 35.100, 35.200, 35.300 parenteral administration of any	(limited to the oral administration obtained to the oral administration obtained to the oral administration of 5.1000 (limited to yttrium-90 as S	adionuclide with a photon
Anil Kothari, M.D.		300 (limited to the oral administrat	
Jeffrey M. Huth, M.D.	41 10 CFR 35:100 and 35.200		
Maximo V. Bleza, D.O.	10 CFR 35:100, 35:200 and 35.	300	
James M. Forde, M.D.	10 CFR 35.100, 35/200 and 35.	300	
Sandeep Sehgal, M.D.	10 CFR 35.200		
Jeffrey Jon Quackenbush, M.D.	() 10 CFR 35.300 and 35.400	little States	
Amjad Alkadri, M.D.	🔿 10 CFR 35.100, 35.200, 35.300	and 35.1000 (limited to yttrium-90	as SIR-Spheres)
Omar Barakat, M.D.		100 (limited to the oral administrat any beta-emitter, or photon-emittir 15.1000 (limited to yttrium-90 as S	ig radionuclide with a photo
Jay D. Shah, M.D.	10 CFR 35.100 and 35.200		
Steven L. Hossler, M.D.	10 CFR 35 100 and 35.200	×	
Akram Kholoki, M.D.	10 CFR 35.100 and 35.200	,	

NRC FORM 374A	U.S. NUCLEAR REGULATORY COM	PAGE 4 OF 4 PAGES	
MATERIALS LICENSE	License Number 13-17073-01	Docket or Reference Number 030-12150	
SUPPLEMENTARY SHEET	Amendment No. 50		
	vise in this license, the licensee shall cond ained in the documents, including any enc		

- those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 21, 2013 (ML13183A468)
- B. Letter dated August 4, 2015 (ML15224B609)
- C. Letter dated September 22, 2017 (ML17268A220)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By:

Colleen Carol Casey **Region 3**

O'SSIMM

Date: January 16, 2018